Synthesis of Schiff Bases of Usnic Acid and Investigation of Their Antidiabetic, Antidepressant, Anti-Parkinson's, Neuroprotective and Antioxidant Potentials.
Lawali Yabo Dambagi, Ahmet Cakir, Mehmet Akyuz, Ayşegül İyidogan, Ali Aslan
{"title":"Synthesis of Schiff Bases of Usnic Acid and Investigation of Their Antidiabetic, Antidepressant, Anti-Parkinson's, Neuroprotective and Antioxidant Potentials.","authors":"Lawali Yabo Dambagi, Ahmet Cakir, Mehmet Akyuz, Ayşegül İyidogan, Ali Aslan","doi":"10.17344/acsi.2024.8703","DOIUrl":null,"url":null,"abstract":"<p><p>Schiff bases have various pharmacological activities due to the azomethine (-C=N-) group. Usnic acid is the most famous lichen metabolite and it contains two carbonyl groups to synthesize the Schiff base derivatives with primary amines. Therefore, in the current study, the known Schiff base derivatives (2-5) of usnic acid (1) were synthesized to explore their antidiabetic, neuroprotective, antioxidant, antidepressant and anti-Parkinson's properties. Among the tested compounds, compound 4 exhibited the strongest antidiabetic and antidepressant activities, inhibiting α-glycosidase, α-amylase and MAO-A enzyme activities, respectively. Moreover, all of the tested compounds strongly scavenged the ABTS and DPPH radicals and the ABTS radical scavenging activities of 3 and 4 were found to be higher than the commercial antioxidants BHA and trolox. All of the tested compounds did not show any significant anti-Parkinson's and neuroprotective activities. In conclusion, compound 4 can be suggested as a drug candidate molecule for further studies due to its strong antioxidant, antidiabetic and antidepressant properties.</p>","PeriodicalId":7122,"journal":{"name":"Acta Chimica Slovenica","volume":"71 4","pages":"566-579"},"PeriodicalIF":1.3000,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Chimica Slovenica","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.17344/acsi.2024.8703","RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Schiff bases have various pharmacological activities due to the azomethine (-C=N-) group. Usnic acid is the most famous lichen metabolite and it contains two carbonyl groups to synthesize the Schiff base derivatives with primary amines. Therefore, in the current study, the known Schiff base derivatives (2-5) of usnic acid (1) were synthesized to explore their antidiabetic, neuroprotective, antioxidant, antidepressant and anti-Parkinson's properties. Among the tested compounds, compound 4 exhibited the strongest antidiabetic and antidepressant activities, inhibiting α-glycosidase, α-amylase and MAO-A enzyme activities, respectively. Moreover, all of the tested compounds strongly scavenged the ABTS and DPPH radicals and the ABTS radical scavenging activities of 3 and 4 were found to be higher than the commercial antioxidants BHA and trolox. All of the tested compounds did not show any significant anti-Parkinson's and neuroprotective activities. In conclusion, compound 4 can be suggested as a drug candidate molecule for further studies due to its strong antioxidant, antidiabetic and antidepressant properties.
希夫碱由于具有亚甲基(- c =N-)基团而具有多种药理活性。Usnic酸是地衣最著名的代谢物,它含有两个羰基,可以与伯胺合成席夫碱衍生物。因此,本研究合成了已知的usnic酸(1)的希夫碱衍生物(2-5),探索其抗糖尿病、神经保护、抗氧化、抗抑郁和抗帕金森病的特性。其中化合物4的抗糖尿病和抗抑郁活性最强,分别抑制α-糖苷酶、α-淀粉酶和MAO-A酶的活性。此外,所有化合物对ABTS和DPPH自由基的清除能力均较强,其中3和4对ABTS自由基的清除能力高于商业抗氧化剂BHA和trolox。所有被测试的化合物都没有显示出任何显著的抗帕金森病和神经保护活性。综上所述,化合物4具有较强的抗氧化、抗糖尿病和抗抑郁作用,可作为候选药物进行进一步研究。
期刊介绍:
Is an international, peer-reviewed and Open Access journal. It provides a forum for the publication of original scientific research in all fields of chemistry and closely related areas. Reviews, feature, scientific and technical articles, and short communications are welcome.